Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

Laurent Ma Favié; Jean-Luc Murk; Adam Meijer; A Laura Nijstad; Erik M van Maarseveen; Maaike A Sikma

doi:10.3851/IMP3210

Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

Laurent Ma Favié^*
, Jean-Luc Murk
, Adam Meijer
, A Laura Nijstad
, Erik M van Maarseveen
, Maaike A Sikma

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

Original language	English
Pages (from-to)	457-461
Number of pages	5
Journal	Antiviral Therapy
Volume	23
Issue number	5
Early online date	29 Nov 2017
DOIs	https://doi.org/10.3851/IMP3210
Publication status	Published - 2018

Keywords

Journal Article
Intensive Care Units
Tertiary Care Centers
Humans
Middle Aged
Critical Illness
Influenza, Human/drug therapy
Male
Hemofiltration/methods
Netherlands
Oseltamivir/administration & dosage
Amides/pharmacokinetics
Pyrazines/pharmacokinetics
Fatal Outcome
Antiviral Agents/pharmacokinetics

Access to Document

10.3851/IMP3210

favie-et-al-2017-pharmacokinetics-of-favipiravir-during-continuous-venovenous-haemofiltration-in-a-critically-illFinal published version, 162 KBLicence: Taverne

Cite this

@article{413f1c7653564751998d48b8af0c49aa,

title = "Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza",

abstract = "Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.",

keywords = "Journal Article, Intensive Care Units, Tertiary Care Centers, Humans, Middle Aged, Critical Illness, Influenza, Human/drug therapy, Male, Hemofiltration/methods, Netherlands, Oseltamivir/administration \& dosage, Amides/pharmacokinetics, Pyrazines/pharmacokinetics, Fatal Outcome, Antiviral Agents/pharmacokinetics",

author = "Favi{\'e}, \{Laurent Ma\} and Jean-Luc Murk and Adam Meijer and Nijstad, \{A Laura\} and \{van Maarseveen\}, \{Erik M\} and Sikma, \{Maaike A\}",

note = "Funding Information: J-LM reports personal fees from Biogen, personal fees from Teva and a grant from Chimerix, outside the submitted work. All other authors report no (potential) conflicts of interest. Publisher Copyright: {\textcopyright}2018 International Medical Press",

year = "2018",

doi = "10.3851/IMP3210",

language = "English",

volume = "23",

pages = "457--461",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "Sage Publications",

number = "5",

}

TY - JOUR

T1 - Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

AU - Favié, Laurent Ma

AU - Murk, Jean-Luc

AU - Meijer, Adam

AU - Nijstad, A Laura

AU - van Maarseveen, Erik M

AU - Sikma, Maaike A

N1 - Funding Information: J-LM reports personal fees from Biogen, personal fees from Teva and a grant from Chimerix, outside the submitted work. All other authors report no (potential) conflicts of interest. Publisher Copyright: ©2018 International Medical Press

PY - 2018

Y1 - 2018

N2 - Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

AB - Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

KW - Journal Article

KW - Intensive Care Units

KW - Tertiary Care Centers

KW - Humans

KW - Middle Aged

KW - Critical Illness

KW - Influenza, Human/drug therapy

KW - Male

KW - Hemofiltration/methods

KW - Netherlands

KW - Oseltamivir/administration & dosage

KW - Amides/pharmacokinetics

KW - Pyrazines/pharmacokinetics

KW - Fatal Outcome

KW - Antiviral Agents/pharmacokinetics

UR - https://www.scopus.com/pages/publications/85055623736

U2 - 10.3851/IMP3210

DO - 10.3851/IMP3210

M3 - Article

C2 - 29185991

SN - 1359-6535

VL - 23

SP - 457

EP - 461

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 5

ER -

Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this